1550 / 1708
P
= .004
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7 8 9 10
Time Since Diagnosis (years)
PFS (probability)
GTR
STR
63 57 55 51 43 40 34 28 21 15 12
27 22 17 15 11 11 10 8 8 6 5
GTR
STR
No. at risk
A
P
= .008
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7 8 9 10
Time Since Diagnosis (years)
OS (probability)
GTR
STR
GTR
STR
GTR
STR
64 59 57 52 44 40 34 29 22 16 13
27 23 20 18 13 13 12 8 8 6 5
GTR
STR
No. at risk
B
P
= .02
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7 8 9 10
Time Since Diagnosis (years)
PFS (probability)
24 24 21 17 14 12 9 6 5 4 2
23 18 14 10 8 5 4 3 2 1 1
GTR
STR
No. at risk
C
P
= .06
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7 8 9 10
Time Since Diagnosis (years)
OS (probability)
23 23 21 17 14 12 10 8 6 4 2
23 21 19 16 14 10 7 5 4 2 1
GTR
STR
No. at risk
D
Fig A7.
Progression-free survival (PFS) and overall survival (OS) EPN_PFB strati
fi
ed by extent of resection for (A and B) the combined Global Ependymoma Network of
Excellence (GENE), St Jude
’
s, and Collaborative Ependymoma Research Network (CERN) cohorts and (C and D) the Burdenko Cohort. GTR, gross total resection; STR,
subtotal resection.
www.jco.org© 2016 by American Society of Clinical Oncology
Treatment of Posterior Fossa Ependymoma Subgroups
from 139.18.224.1
Information downloaded from
jco.ascopubs.organd provided by at UNIVERSITAETSKLINIKUM LEIPZIG on June 20, 2016
Copyright © 2016 American S ciety of Clinical Oncology. All rights reserved.